Following through on the divestiture strategy it announced last May, Genzyme Corp. will sell Genzyme Genetics to LabCorp for $925 million in cash. LabCorp will purchase the business in its entirety, including all testing services, technology, IP rights, and nine testing laboratories. LabCorp will offer employment to the unit’s approximately 1,900 employees upon closing, including senior management. The companies hope to close the deal before the end of the year. “This transaction demonstrates...